In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cellestis Ltd.

Division of Qiagen NV
www.cellestis.com

Latest From Cellestis Ltd.

Matchmaking And Integration In The New World Of Diagnostics M&A

Nontraditional buyers, including Big Pharmas, life science tool companies, diversified conglomerates, and even food companies, are snapping up molecular diagnostics assets with increasing frequency, applying a variety of models to enhance their businesses.

Medical Device BioPharmaceutical

Medical Device and In Vitro Diagnostics/Research Deals Statistics Quarterly, Q2 2011

During the second quarter of 2011, 57 medical device companies brought in a total of $1.7 billion in financings. The M&A activity reached $28.8 billion, unusually high due to Johnson & Johnson's $21.7 billion takeover of orthopedic device maker Synthes. VC funding represented $76 million or 43% of the second quarter's in vitro diagnostics/research financing aggregate of $177 million. A hefty $4.1 billion was spent on 11 in vitro diagnostic/research M&A transactions, the largest being Thermo Fisher's $3.5 billion buy of Swedish genetics testing firm Phadia AB.
Medical Device

Deals Update

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
Medical Device

Deals Shaping the Medical Industry (04/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Australia
  • Parent & Subsidiaries
  • Qiagen NV
  • Senior Management
  • Anthony Radford, PhD, Managing Dir. & CEO
    Brian Manuel, CFO
    James Rothel, PhD, CSO
  • Contact Info
  • Cellestis Ltd.
    Phone: (61) 3 8527 3500
    1341 Dandenong Rd.
    P.O. Box 169 Chadstone, 3148
    Australia
Advertisement
Advertisement
UsernamePublicRestriction

Register